[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myasthenia-gravis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":243,"states":256},"Myasthenia Gravis",38,33,[8,16,23,29,35,41,47,54,60,67,73,79,85,91,98,104,110,116,122,128,134,140,146,152,158,163,169,175,181,187,192,197,203,209,216,223,229,236],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07673744","A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-07-05T03:45:20.432625Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07596901","Study of Aritinercept in Patients With Generalized Myasthenia Gravis",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:09.079045Z","2026-05-29T15:36:40.205712Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06414954","Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis",[12],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.682664Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07501702","A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.044523Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06491238","Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis",[],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.989139Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":21,"content_modified":46},"NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases",[45],"Phase 1","2026-05-05T02:43:28.963761Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT06193889","KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",[51],"Phase 2\u002FPhase 3","2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.850397Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06220201","A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",[45],"2026-08-03T03:02:58.488119Z","2026-05-05T02:43:28.742927Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT06799247","Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",[64],"Phase 3","2026-08-26T02:19:05.360997Z","2026-05-05T02:43:28.368378Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06456580","A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)",[64],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:28.186357Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05265273","A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis",[51],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:27.917520Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07217587","Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis",[64],"2026-08-26T02:16:06.684983Z","2026-05-05T02:43:27.402784Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04951622","A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis",[64],"2026-08-26T02:19:31.671303Z","2026-05-05T02:35:31.762106Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT06860633","Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod",[95],"Phase 4","2026-08-26T02:15:33.331531Z","2026-04-29T02:57:57.101290Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06680037","A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders",[45],"2026-08-26T02:19:12.219640Z","2026-07-05T05:32:16.768710Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07304154","A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed\u002FRefractory Autoimmune Neurologic Diseases",[45],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:29.387936Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07089121","Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders",[20],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.171088Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease",[],"2026-08-26T02:18:04.640417Z","2026-04-29T02:57:57.124114Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07673627","ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis",[12],"2026-08-26T02:15:04.877798Z","2026-07-30T01:46:14.444070Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07294170","ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis",[],"2026-08-26T02:18:09.641312Z","2026-05-13T02:55:06.684303Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06866483","Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment",[],"2026-08-26T02:19:02.550788Z","2026-05-13T02:55:06.585934Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT06617741","Myasthenia Gravis Foundation of America Global MG Patient Registry",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.555834Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06299748","A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and\u002For Breastfeeding.",[],"2026-08-26T02:18:44.395098Z","2026-05-13T02:55:06.434123Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06298565","A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa",[],"2026-08-26T02:15:23.202838Z","2026-05-13T02:55:06.433442Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":27,"content_modified":162},"NCT06064461","Vitaccess Real MG Registry",[],"2026-05-13T02:55:06.405280Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT03792659","The EXPLORE MG Registry for Myasthenia Gravis",[],"2026-08-26T02:16:01.910993Z","2026-05-13T02:55:06.175686Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07220915","Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",[64],"2026-08-26T02:17:05.997056Z","2026-07-24T01:27:14.901588Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.700539Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06940323","Pregnancy Registry, Infants, Serum\u002FMilk Analysis (PRISMA)",[],"2026-08-26T02:19:18.331180Z","2026-05-13T02:55:06.592968Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":150,"content_modified":191},"NCT06539169","FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases",[],"2026-05-13T02:55:06.551987Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":167,"content_modified":196},"NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research",[],"2026-05-13T02:55:06.271836Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.077983Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT05564936","The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis",[],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:26.955239Z",{"nct_id":210,"title":211,"phases":212,"status":213,"updated_at":214,"content_modified":215},"NCT07226830","Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG",[],"NOT_YET_RECRUITING","2026-08-26T02:15:22.311223Z","2026-05-13T02:55:06.678641Z",{"nct_id":217,"title":218,"phases":219,"status":220,"updated_at":221,"content_modified":222},"NCT07217509","PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry",[],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.872332Z",{"nct_id":224,"title":225,"phases":226,"status":220,"updated_at":227,"content_modified":228},"NCT00704626","Serum Auto-Antibodies in Neurological Diseases",[],"2026-08-26T02:19:25.538428Z","2026-06-16T05:54:07.944323Z",{"nct_id":230,"title":231,"phases":232,"status":233,"updated_at":234,"content_modified":235},"NCT06106672","Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:10:37.231905Z","2026-05-05T02:43:29.389907Z",{"nct_id":237,"title":238,"phases":239,"status":240,"updated_at":241,"content_modified":242},"NCT05635266","Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives",[],"UNKNOWN","2026-08-03T02:15:56.082035Z","2026-05-13T02:55:06.368062Z",[244,248,252],{"biomarker":245,"count":246,"slug":247},"Acetylcholine Receptor",10,"acetylcholine-receptor",{"biomarker":249,"count":250,"slug":251},"Muscle, Skeletal Receptor Tyrosine-Protein Kinase",5,"muscle-skeletal-receptor-tyrosine-protein-kinase",{"biomarker":253,"count":254,"slug":255},"Autoantibody",3,"autoantibody",[257,261,265,269,272,275,278,281,285,288,292,295,298,302,305,309,312,315,318,321,324,327,330],{"state":258,"count":259,"slug":260},"California",20,"california",{"state":262,"count":263,"slug":264},"Florida",16,"florida",{"state":266,"count":267,"slug":268},"Texas",12,"texas",{"state":270,"count":246,"slug":271},"Colorado","colorado",{"state":273,"count":246,"slug":274},"Massachusetts","massachusetts",{"state":276,"count":246,"slug":277},"Michigan","michigan",{"state":279,"count":246,"slug":280},"New York","new-york",{"state":282,"count":283,"slug":284},"Illinois",9,"illinois",{"state":286,"count":283,"slug":287},"Ohio","ohio",{"state":289,"count":290,"slug":291},"Missouri",8,"missouri",{"state":293,"count":290,"slug":294},"North Carolina","north-carolina",{"state":296,"count":290,"slug":297},"Oregon","oregon",{"state":299,"count":300,"slug":301},"Kansas",7,"kansas",{"state":303,"count":300,"slug":304},"Tennessee","tennessee",{"state":306,"count":307,"slug":308},"Arizona",6,"arizona",{"state":310,"count":307,"slug":311},"Wisconsin","wisconsin",{"state":313,"count":250,"slug":314},"Connecticut","connecticut",{"state":316,"count":250,"slug":317},"Kentucky","kentucky",{"state":319,"count":250,"slug":320},"Pennsylvania","pennsylvania",{"state":322,"count":250,"slug":323},"South Carolina","south-carolina",{"state":325,"count":254,"slug":326},"Georgia","georgia",{"state":328,"count":254,"slug":329},"Indiana","indiana",{"state":331,"count":254,"slug":332},"Washington","washington"]